Silk et al. [91] revealed that high-dose anti-CTLA4 and IL-2 therapy demonstrated that granzyme B levels and the HLA-DM/HLA-DO ratio are reliable blood biomarkers for predicting treatment response, which is associated with decreased tumor size. This evidence concerns the gene CTLA4 and neoplasm.